“HOSPITAL-BASED STUDY TO ASSESS THE EFFECTIVENESS AND SAFETY OF ANTIDIABETIC MONOTHERAPY IN CONTRAST TO COMBINATION THERAPY”

OLIVER STEEVO PINTO; RAKSHITH SHETTY; U. Y. FAREENA FAIZAL; ASHNA SAYISH; CHRISTY T. CHACKO; A. R. SHABARAYA

doi:10.22159/ijcpr.2025v17i6.8004

Authors

OLIVER STEEVO PINTO Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore-574143, India
RAKSHITH SHETTY Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore-574143, India
U. Y. FAREENA FAIZAL Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore-574143, India
ASHNA SAYISH Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore-574143, India
CHRISTY T. CHACKO Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore-574143, India
A. R. SHABARAYA Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore-574143, India

DOI:

https://doi.org/10.22159/ijcpr.2025v17i6.8004

Keywords:

Type 2 diabetes mellitus, Antidiabetic therapy, Glycemic control, Adverse drug reactions, Cost-minimization

Abstract

Objective: This study aims to compare the effectiveness and safety of antidiabetic monotherapy versus combination therapy in managing T2DM.

Methods: A prospective, observational study was conducted over six months in the general medicine department, involving 152 inpatients with T2DM. Patients aged 18 or above, with HbA1c ≥ 6.5% and/or GRBS ≥ 200 mg/dl, and on either monotherapy or combination therapy were included. Data were collected from patient records and caregivers.

Results: The results indicated that combination therapy demonstrated superior glycemic control compared to monotherapy, which was statistically significant (p<0.05). Monotherapy was prevalent, with biguanides and sulphonylureas being the most prescribed drugs. However, combination therapy showed a higher incidence of adverse drug reactions (ADRs), particularly among older patients. Metformin was identified as the safest oral hypoglycemic agent (OHA). The study also revealed significant cost savings when using Jan Aushadhi medications compared to branded alternatives.

Conclusion: The findings underscore the necessity for regular blood glucose monitoring and personalized treatment plans to manage T2DM effectively. The study highlights the economic advantages of prescribing low-cost generics, which can improve medication adherence and health outcomes, especially in financially constrained patients. The integration of lifestyle modifications with pharmacotherapy is crucial for enhanced glycemic control. This study emphasizes the importance of combination therapy for better glycemic control in T2DM while acknowledging the increased risk of ADRs. It advocates for the economic benefits of Jan Aushadhi drugs, suggesting a cost-effective approach to diabetes management. Healthcare providers must focus on comprehensive care, integrating clinical guidelines and promoting interdisciplinary collaboration to improve patient outcomes.

Downloads

Download data is not yet available.

References

1. Ganga S, Shareef S, Tadvi N, Siddiqua S. A comparative study of efficacy and adverse effects of monotherapy with combination therapy for oral anti-diabetics in diabetes mellitus type 2 patients. Natl J Physiol Pharm Pharmacol. 2021;11(6):1-5. doi: 10.5455/njppp.2021.11.01021202126012021.

2. Samya V, Shriraam V, Jasmine A, Akila GV, Anitha Rani M, Durai V. Prevalence of hypoglycemia among patients with type 2 diabetes mellitus in a rural health center in South India. J Prim Care Community Health. 2019;10:2150132719880638. doi: 10.1177/2150132719880638, PMID 31631765.

3. Tripathy JP, Sagili KD, Kathirvel S, Trivedi A, Nagaraja SB, Bera OP. Diabetes care in public health facilities in India: a situational analysis using a mixed methods approach. Diabetes Metab Syndr Obes. 2019;12:1189-99. doi: 10.2147/DMSO.S192336, PMID 31410044.

4. Xie X, Wu C, Hao Y, Wang T, Yang Y, Cai P. Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review. Front Endocrinol. 2023;14:1301093. doi: 10.3389/fendo.2023.1301093, PMID 38179301.

5. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30-7. doi: 10.1111/dom.12174, PMID 23803146.

6. Ji L, Chan JC, Yu M, Yoon KH, Kim SG, Choi SH. Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: an East Asian perspective. Diabetes Obes Metab. 2021;23(1):3-17. doi: 10.1111/dom.14205, PMID 32991073.

7. Gao W, Dong J, Liu J, Li Y, Liu F, Yang L. Efficacy and safety of initial combination of DPP‐IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Obesity Metabolism. 2014;16(2):179-85. doi: 10.1111/dom.12193.

8. Ramachandran V, Ambady R, Joshi S. Current status of diabetes in India and need for novel therapeutic agents. JAPI. 2021;58:7-9.

9. Indian Council of Medical Research (ICMR). Guidelines for management of type 2 diabetes 2018. New Delhi: ICMR; 2018. Available from: https://main.icmr.nic.in/sites/default/files/guidelines/icmr_guidelinestype2diabetes2018_0.pdf. [Last accessed on 04 Nov 2025].

10. Davis HA, Spanakis EK, Cryer PE, Davis SN. Hypoglycemia during therapy of diabetes. MDText.com; 2021. Available from: https://www.endotext.org/chapter/hypoglycemia‑during‑therapy‑of‑diabetes/.

11. Pati S, Schellevis FG. Prevalence and pattern of co-morbidity among type 2 diabetics attending urban primary healthcare centers at Bhubaneswar (India). PloS One. 2017;12(8):e0181661. doi: 10.1371/journal.pone.0181661, PMID 28841665.

12. Nagarathna R, Madhava M, Patil SS, Singh A, Perumal K, Ningombam G. Cost of management of diabetes mellitus: a pan India study. Ann Neurosci. 2020;27(3-4):190-2. doi: 10.1177/0972753121998496, PMID 34556959.

13. Keezhipadathil J. Evaluation of suspected adverse drug reactions of oral anti-diabetic drugs in a Tertiary Care Hospital for type II diabetes mellitus. Indian J Pharm Pract. 2019;12(2):103-10. doi: 10.5530/ijopp.12.2.23.

14. Ponnachan R, Babu B, Yesodhar S, Utangi S. Drug utilization evaluation of anti-diabetics in type 2 diabetes mellitus patients with or without comorbidities in a Tertiary Care Teaching Hospital. J Young Pharm. 2021;13(3):267-9. doi: 10.5530/jyp.2021.13.54.

15. Tschope D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol. 2013;12(1):62. doi: 10.1186/1475-2840-12-62, PMID 23574917.

16. Mamatha J, Palatty P, Sachendran D, Vijendra R, Baliga M. Financial benefit of antidiabetic drugs available at Jan Aushadhi (people’s drug) stores to geriatric pensioners: a pilot study from India. Hamdan Med J. 2022;15(2):66. doi: 10.4103/hmj.hmj_64_21.

17. Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm. 2014;5(3):79-83. doi: 10.4103/0976-0105.139731, PMID 25278671.

18. Babu A, Mehta A, Guerrero P, Chen Z, Meyer PM, Koh CK. Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Endocr Pract. 2009;15(7):696-704. doi: 10.4158/EP09117.ORR, PMID 19625243.

19. Bhattacharjee A, Gupta MC, Agrawal S. Adverse drug reaction monitoring of newer oral anti diabetic drugs-a pharmacovigilance perspective. Int J Pharmacol Res. 2016;6(4):142-51.

20. Tirthankar D, Abhik C, Abhishek G. Adverse drug reactions in type 2 diabetes mellitus patients on oral antidiabetic drugs in a diabetes outpatient department of a Tertiary Care Teaching Hospital in the Eastern India. Int J Med Sci Public Health. 2017;6(3):554-7. doi: 10.5455/ijmsph.2017.0423203102016.

21. Javedh S, Jennifer F, Laxminarayana S, Shifaz AK. A study on adverse drug reactions in hospitalized patients with diabetes mellitus in a multi-specialty teaching hospital. Asian J Pharm Clin Res. 2016;9(2):114-7.

22. Rajesh R, Ramesh M, Parthasarathi G. A study on adverse drug reactions related hospital admission and their management. Indian J Hosp Pharm. 2008;45:143-8.

23. Sahay RK, Mittal V, Gopal GR, Kota S, Goyal G, Abhyankar M. Glimepiride and metformin combinations in diabetes comorbidities and complications: real-world evidence. Cureus. 2020;12(9):e10700. doi: 10.7759/cureus.10700, PMID 33133865.

24. Chaudhary RK, Philip MJ, Santhosh A, Karoli SS, Bhandari R, Ganachari MS. Health economics and effectiveness analysis of generic anti-diabetic medication from Jan Aushadhi: an ambispective study in community pharmacy. Diabetes Metab Syndr. 2021;15(6):102303. doi: 10.1016/j.dsx.2021.102303, PMID 34626923.

25. Mukherjee K. A cost analysis of the Jan Aushadhi scheme in India. Int J Health Policy Manag. 2017;6(5):253-6. doi: 10.15171/ijhpm.2017.02, PMID 28812812.

26. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299-307. doi: 10.2147/PPA.S106821, PMID 27524885.

27. Singh A, Dwivedi S. Study of adverse drug reactions in patients with diabetes attending a Tertiary Care Hospital in New Delhi, India. Indian J Med Res. 2017 Feb;145(2):247-9. doi: 10.4103/ijmr.IJMR_109_16, PMID 28639602.